NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company's broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
NV-387 is a unique broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. It has also shown effectiveness in animal models for monkeypox, smallpox, and measles. The successful completion of a Phase I human clinical trial in healthy volunteers with no reported adverse events positions the drug for Phase II testing. The company is currently focused on advancing NV-387 into Phase II human clinical trials, with the monkeypox trial in the DRC being a key priority.
The presentation at the NIBA conference provides an opportunity for NanoViricides to update investors on its progress. The company's lead drug candidate, NV-387, represents a novel approach using special purpose nanomaterials for antiviral therapy. The completion of the Oral Gummies manufacturing is a significant milestone, as it ensures the drug product is ready for dosing once clinical sites are prepared. This development underscores the company's commitment to addressing unmet medical needs in viral infections, particularly in regions like the DRC where monkeypox remains a public health concern.
For more details, the full press release is available at https://ibn.fm/AILOVA. Additional updates on NNVC can be found in the company's newsroom at https://ibn.fm/NNVC.
